By Jasmine Li
Pulse Biosciences reported positive preliminary results from its clinical study of a treatment for benign thyroid nodules.
The Miami-based company's Nanosecond Pulsed Field Ablation technology reduced nodule sizes on average by more than 50%, it said on Thursday.
The 30-patient feasibility study also found that the technology provided symptomatic relief within the first month of treatment, and showed no evidence of residual fibrosis or scarring, the company said.
These results suggest that nano-PFA energy can provide symptomatic relief to patients with benign thyroid nodules across the first month after the treatment, Chief Executive Burke Barrett said.
The company intends to commence a pivotal trial in mid-2025 designed to support a specific labeling indication to commercialize the system in the U.S., Barrett said.
Write to Jasmine Li at jasmine.li@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
October 31, 2024 15:12 ET (19:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。